Gareth L. Bond

Medicine · Health Sciences

29h-index5.0kcitations138works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(61), Epigenetics and DNA Methylation(30), RNA modifications and cancer(25), Cancer Genomics and Diagnostics(24), HIV/AIDS drug development and treatment(18)

Publications138 total

Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
2025Open Access
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
2025Open Access
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
2025Open Access
Table S2 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024Open Access
Supplementary Figure 2 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024Open Access
Supplementary Figure 3 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024Open Access
Supplementary Figure 4 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024Open Access
Figure 2 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024Open Access
Figure 6 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024Open Access
Figure 1 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024Open Access
Table S1 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024Open Access
Supplementary Figure 6 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024Open Access
Supplementary Figure 5 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024Open Access
Figure 5 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024Open Access
Supplementary Materials from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024Open Access
Supplementary Figure 2E from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024Open Access
Supplementary Figure 1 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024Open Access
Table S3 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024Open Access
Data from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024Open Access
Figure 3 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
2024Open Access
page 1 of 7Next →

Frequent Co-authors

Arnold J. Levine(16), Elisabeth E. Bond(14), Lukasz F. Grochola(12), Ping Zhang(10), Helge Täubert(8), Marsha D. Wallace(7), Wenwei Hu(5), Giovanni Stracquadanio(5), Xuting Wang(5), Jorge Zerón-Medina(5), Douglas A. Bell(5), Sarah De Val(5), Lingyun Xiong(5), Peter Würl(5), Harlan Robins(4), Frank Bartel(4), Peter Wuerl(4), Alexei Vázquez(4), Kim M. Hirshfield(4), Anna M. Grawenda(4)